• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于紫杉烷的化疗诱导去势抵抗性前列腺癌患者的雄激素受体剪接变异体 7:一项基于组织的分析。

Taxane-based Chemotherapy Induced Androgen Receptor Splice Variant 7 in Patients with Castration-Resistant Prostate Cancer: A Tissue-based Analysis.

机构信息

Department of Urology, Hallym University College of Medicine, Hallym University Sacred Heart Hospital, 22, Gwanpyeong-ro 170beon-gil, Dongan-gu, Anyang-si, Gyeonggi-do, 14068, South Korea.

Institute for Innovative Cancer Research, Asan Institute for Life Science, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.

出版信息

Sci Rep. 2019 Nov 14;9(1):16794. doi: 10.1038/s41598-019-53280-5.

DOI:10.1038/s41598-019-53280-5
PMID:31727962
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6856155/
Abstract

In total, 95 prostate cancer (Pca) patients who underwent transurethral resection of the prostate from 2000 to 2013 were assigned to four groups: Group 1, hormone-naïve and T1a or T1b Pca (n = 17); Group 2, hormone-sensitive and metastatic Pca (n = 33); Group 3, chemo-naïve castration-resistant Pca (CRPC), (n = 18); and Group 4, CRPC with chemotherapy (n = 27). Full-length androgen receptor (ARfl) transcript levels significantly increased from Group 1 through to Group 3 (p = 0.045), but decreased from Group 3 through to Group 4. AR splice variant 7 (ARV7) and glucocorticoid receptor (GR) transcript levels significantly increased from Group 1 through to Group 4 (p = 0.002 and 0.049, respectively). Kaplan-Meier curve revealed that the high transcript level of these three receptors resulted in significantly poorer cancer-specific survival (CSS) than that by low transcript level, although Cox regression analysis revealed that the ARV7 level alone was an independent prognostic factor for CSS in CRPC patients (high vs. low: hazard ratio, 1.897; 95% confidence interval, 1.102-3.625; p = 0.042). In conclusion, ARV7 and GR transcript levels significantly increase as Pca progresses to CRPC.

摘要

共有 95 例前列腺癌(Pca)患者于 2000 年至 2013 年接受经尿道前列腺切除术,将其分为四组:组 1,激素初治且肿瘤局限于 T1a 或 T1b(n=17);组 2,激素敏感且发生转移的 Pca(n=33);组 3,化疗初治的去势抵抗性前列腺癌(CRPC)(n=18);组 4,接受化疗的 CRPC(n=27)。全长雄激素受体(ARfl)转录本水平从组 1 到组 3 显著增加(p=0.045),但从组 3 到组 4 降低。AR 剪接变异体 7(ARV7)和糖皮质激素受体(GR)转录本水平从组 1 到组 4 显著增加(p=0.002 和 0.049)。Kaplan-Meier 曲线表明,这三种受体的高转录本水平导致癌症特异性生存(CSS)明显低于低转录本水平,尽管 Cox 回归分析表明,在 CRPC 患者中,仅 ARV7 水平是 CSS 的独立预后因素(高 vs. 低:风险比,1.897;95%置信区间,1.102-3.625;p=0.042)。总之,随着前列腺癌进展为 CRPC,ARV7 和 GR 转录本水平显著增加。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fd/6856155/2366d23f6e48/41598_2019_53280_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fd/6856155/c9836873c0e7/41598_2019_53280_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fd/6856155/41285cb48908/41598_2019_53280_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fd/6856155/2366d23f6e48/41598_2019_53280_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fd/6856155/c9836873c0e7/41598_2019_53280_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fd/6856155/41285cb48908/41598_2019_53280_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fd/6856155/2366d23f6e48/41598_2019_53280_Fig3_HTML.jpg

相似文献

1
Taxane-based Chemotherapy Induced Androgen Receptor Splice Variant 7 in Patients with Castration-Resistant Prostate Cancer: A Tissue-based Analysis.基于紫杉烷的化疗诱导去势抵抗性前列腺癌患者的雄激素受体剪接变异体 7:一项基于组织的分析。
Sci Rep. 2019 Nov 14;9(1):16794. doi: 10.1038/s41598-019-53280-5.
2
ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.ARv7 抑制去势抵抗性前列腺癌中的肿瘤抑制基因。
Cancer Cell. 2019 Mar 18;35(3):401-413.e6. doi: 10.1016/j.ccell.2019.01.008. Epub 2019 Feb 14.
3
Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer.雄激素受体及其剪接变异体 7 在转移性去势抵抗性前列腺癌患者外周血单个核细胞和循环肿瘤细胞中的表达。
Cells. 2020 Jan 14;9(1):203. doi: 10.3390/cells9010203.
4
Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.激素敏感性前列腺癌和去势抵抗性前列腺癌中雄激素受体变异体7和泛素结合酶2C的转录水平
Prostate. 2017 Jan;77(1):60-71. doi: 10.1002/pros.23248. Epub 2016 Aug 22.
5
Androgen receptor splice variants determine taxane sensitivity in prostate cancer.雄激素受体剪接变异体决定前列腺癌对紫杉烷类药物的敏感性。
Cancer Res. 2014 Apr 15;74(8):2270-2282. doi: 10.1158/0008-5472.CAN-13-2876. Epub 2014 Feb 20.
6
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.雄激素受体剪接变异体-7 的表达随着前列腺癌的去势抵抗而出现。
J Clin Invest. 2019 Jan 2;129(1):192-208. doi: 10.1172/JCI122819. Epub 2018 Nov 26.
7
Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells.雄激素受体剪接变异体 7 在前列腺癌细胞中独立于全长受体发挥作用。
Cancer Lett. 2021 Oct 28;519:172-184. doi: 10.1016/j.canlet.2021.07.013. Epub 2021 Jul 10.
8
Androgen receptors in hormone-dependent and castration-resistant prostate cancer.雄激素受体在激素依赖性和去势抵抗性前列腺癌中的作用。
Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13.
9
Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.靶向 Hsp40/Hsp70 伴侣蛋白轴作为一种治疗去势抵抗性前列腺癌的新策略。
Cancer Res. 2018 Jul 15;78(14):4022-4035. doi: 10.1158/0008-5472.CAN-17-3728. Epub 2018 May 15.
10
The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells.去势抵抗性前列腺癌细胞中雄激素受体剪接变体的顺式作用元件组和基因特征
J Urol. 2015 Feb;193(2):690-8. doi: 10.1016/j.juro.2014.08.043. Epub 2014 Aug 14.

引用本文的文献

1
The Emerging Roles of the Stress Epigenetic Reader LEDGF/p75 in Cancer Biology and Therapy Resistance: Mechanisms and Targeting Opportunities.应激表观遗传读取蛋白LEDGF/p75在癌症生物学和治疗抗性中的新作用:机制与靶向机会
Cancers (Basel). 2024 Nov 26;16(23):3957. doi: 10.3390/cancers16233957.
2
Alternative splicing in prostate cancer progression and therapeutic resistance.前列腺癌进展和治疗抵抗中的可变剪接。
Oncogene. 2024 May;43(22):1655-1668. doi: 10.1038/s41388-024-03036-x. Epub 2024 Apr 24.
3
Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancer.

本文引用的文献

1
Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancer.雄激素受体(AR)剪接变体7和全长AR表达与临床结局相关:一项去势抵抗性前列腺癌患者的转化研究。
BJU Int. 2019 Oct;124(4):693-700. doi: 10.1111/bju.14792.
2
Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy.雄激素受体剪接变体7驱动去势抵抗性前列腺癌的生长,且不参与紫杉烷化疗的疗效。
J Clin Med. 2018 Nov 16;7(11):444. doi: 10.3390/jcm7110444.
3
抑制丝氨酸/苏氨酸激酶BUB1可逆转前列腺癌对紫杉烷的耐药性。
iScience. 2023 Aug 18;26(9):107681. doi: 10.1016/j.isci.2023.107681. eCollection 2023 Sep 15.
4
Glucocorticoid Receptor Regulates and Interacts with LEDGF/p75 to Promote Docetaxel Resistance in Prostate Cancer Cells.糖皮质激素受体调节并与 LEDGF/p75 相互作用,促进前列腺癌细胞对多西他赛的耐药性。
Cells. 2023 Aug 11;12(16):2046. doi: 10.3390/cells12162046.
5
Glucocorticoid Receptor and β-Catenin Interact in Prostate Cancer Cells and Their Co-Inhibition Attenuates Tumorsphere Formation, Stemness, and Docetaxel Resistance.糖皮质激素受体和β-连环蛋白在前列腺癌细胞中相互作用,其共同抑制减弱肿瘤球形成、干性和多西紫杉醇耐药性。
Int J Mol Sci. 2023 Apr 12;24(8):7130. doi: 10.3390/ijms24087130.
6
Prognostic Significance of Glucocorticoid Receptor Expression in Cancer: A Systematic Review and Meta-Analysis.糖皮质激素受体表达在癌症中的预后意义:一项系统评价与Meta分析
Cancers (Basel). 2021 Apr 1;13(7):1649. doi: 10.3390/cancers13071649.
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
雄激素受体剪接变异体-7 的表达随着前列腺癌的去势抵抗而出现。
J Clin Invest. 2019 Jan 2;129(1):192-208. doi: 10.1172/JCI122819. Epub 2018 Nov 26.
4
Treatment sequence in castration-resistant prostate cancer: A retrospective study in the new anti-androgen era.去势抵抗性前列腺癌的治疗顺序:新抗雄激素时代的一项回顾性研究。
Mol Clin Oncol. 2017 Oct;7(4):601-603. doi: 10.3892/mco.2017.1361. Epub 2017 Aug 3.
5
High levels of the AR-V7 Splice Variant and Co-Amplification of the Golgi Protein Coding YIPF6 in AR Amplified Prostate Cancer Bone Metastases.AR扩增的前列腺癌骨转移中AR-V7剪接变体的高表达及高尔基体蛋白编码基因YIPF6的共扩增
Prostate. 2017 May;77(6):625-638. doi: 10.1002/pros.23307. Epub 2017 Feb 1.
6
Spatial genomic heterogeneity within localized, multifocal prostate cancer.局限性、多灶性前列腺癌的空间基因组异质性。
Nat Genet. 2015 Jul;47(7):736-45. doi: 10.1038/ng.3315. Epub 2015 May 25.
7
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.AR-V7 与前列腺癌中对恩杂鲁胺和阿比特龙的耐药性。
N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3.
8
Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.恩杂鲁胺在未接受多西他赛治疗及已接受多西他赛治疗的转移性去势抵抗性前列腺癌患者中的临床活性。
Prostate. 2014 Nov;74(15):1560-8. doi: 10.1002/pros.22874. Epub 2014 Aug 31.
9
The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.糖皮质激素受体的表达受前列腺肿瘤中雄激素受体信号的正向调节。
Int J Cancer. 2015 Feb 15;136(4):E27-38. doi: 10.1002/ijc.29147. Epub 2014 Aug 27.
10
Dihydrotestosterone enhances castration-resistant prostate cancer cell proliferation through STAT5 activation via glucocorticoid receptor pathway.双氢睾酮通过糖皮质激素受体途径激活信号转导和转录激活因子5(STAT5),从而增强去势抵抗性前列腺癌细胞的增殖。
Prostate. 2014 Sep;74(12):1240-8. doi: 10.1002/pros.22841. Epub 2014 Jul 7.